Oracle Corp (NASDAQ:ORCL) Vice Chairman Jeffrey Henley has completed a substantial reduction of his equity position in the enterprise software giant. On June 24, 2026, Henley sold 400,000 shares of Oracle's common stock, realizing a total value of approximately $63.7 million. The transactions were executed in accordance with a Rule 10b5-1 trading plan, which was formally adopted on January 2, 2026. The shares were sold at prices ranging between $155.50 and $165.57 per share.
These sales followed a preceding transaction under the same 10b5-1 plan, wherein Henley acquired 400,000 shares of Oracle common stock through the exercise of stock options. The option exercise price was set at $40.93 per share, totaling $16,372,000. Prior to this sequence of transactions, Henley held a direct position in the company. Following the recent divestment, his direct holdings of Oracle common stock stand at zero. However, he maintains indirect ownership through several vehicles: 745,000 shares via a Grantor Retained Annuity Trust (GRAT), 455,910 shares through a Trust, and 490,333 shares via the Henley Community Property Trust.
The timing of this executive sale coincides with notable volatility in Oracle's share price. Over the past week, the stock has declined by 17%, closing at $148.61. Despite this recent downward pressure, independent analysis from InvestingPro suggests that Oracle remains undervalued relative to its calculated fair value, placing it on the platform's list of most undervalued stocks. Investors seeking to evaluate the company's valuation metrics can access Oracle's comprehensive Pro Research Report, which is part of a broader database covering over 1,400 US equities.
From a fundamental perspective, Oracle has demonstrated robust performance metrics for fiscal year 2026. The company reported a significant increase in performance obligations, reaching $77 billion. This figure represents 86% of Evercore ISI's revenue estimate for the next twelve months, providing enhanced visibility into future revenue streams. Analyst sentiment remains positive, with Evercore ISI maintaining an Outperform rating and a $245 price target for Oracle.
KeyBanc has also reiterated an Overweight rating on the stock, setting a $300 price target. The firm cited improved clarity regarding the company's expense outlook as a key driver for raising earnings per share estimates for fiscal years 2028 through 2030. These analyst actions highlight confidence in Oracle's long-term financial trajectory despite recent market fluctuations.
Strategically, Oracle is expanding its footprint in critical sectors including healthcare and defense. Oracle Health has deepened its collaboration with Baystate Health to implement AI-powered healthcare technologies across the network in western Massachusetts. Additionally, Oracle Health has partnered with Theator to introduce AI surgical documentation solutions in the United States, integrating surgical video analysis with electronic health record data. Furthermore, Oracle announced the addition of 10 defense technology companies to its Oracle Defense Ecosystem, with a focus on artificial intelligence and cybersecurity capabilities.
These developments underscore Oracle's ongoing commitment to leveraging AI across diverse industries. The company's stock data reflects current market pricing, with a closing price of $148.61, down $3.85 or 2.53% from the previous close. After-hours trading showed a slight recovery to $148.65. The intersection of executive trading activity, analyst valuation models, and strategic sector expansion provides a complex landscape for investors evaluating Oracle's position in the technology sector.